In vitro activity of two old antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus

Journal of Antibiotics

Volumn 63, Issue 11, 2010, Pages 657-659

  Yu, Xu Hong ^a   Song, Xiu Jie ^b   Cai, Yun ^a   Liang, Bei Bei ^a   Lin, De Feng ^a   Wang, Rui ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b NAVY GENERAL HOSPITAL   (China)

Author keywords

fosfomycin; fractional inhibitory concentration (FIC); fusidic acid; methicillin resistant Staphylococcus aureus (MRSA); synergism

Indexed keywords

FOSFOMYCIN; FUSIDIC ACID;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CHINA; DRUG POTENTIATION; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; CHINA; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FOSFOMYCIN; FUSIDIC ACID; GUIDELINES AS TOPIC; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 78649712789     PISSN: 00218820     EISSN: None     Source Type: Journal    
DOI: 10.1038/ja.2010.105     Document Type: Article

References (26)

1. Thornsberry, C. Epidemiology of staphylococcal infections\a USA perspective. J. Chemother. 6(Suppl 2), 61-65 (1994).
2. Vandenbroucke-Grauls, C. Epidemiology of staphylococcal infections\a European perspective. J. Chemother. 6(Suppl 2), 67-70 (1994).
3. Centers for Disease Control and Prevention (CDC). MRSA among ICU Patients, (1995-2004).
4. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October Am. Infect. Control 32, 470-485 (2004).
5. Ho, P. L., Yuen, K., Yam, W., Sai-yin, W. S. & Luk, W. Changing patterns of susceptibilities of blood, urinary and respiratory pathogens in Hong Kong. J. Hosp. Infect. 31, 305-317 (1995).
6. Craven, D. E., Kollisch, N. R., Hseih, C. R., Conolly, M. G. & McCabe, W. R. Vancomycin treatment of bacteremia caused by oxacillin-resistant Staphylococcus aureus: compar-ison with beta-lactam antibiotic treatment of bacteremia caused by oxacillin-sensitive Staphylococcusaureus. J. Infect. Dis. 147, 137-143 (1983).
7. Sorrell, T. C., Packham, D. R., Shanker, S., Foldes, M. & Munro, R. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann. Intern. Med. 97, 3440-3501 (1982).
8. Falagas, M. E., Grammatikos, A. P. & Michalopoulos, A. Potential of old-generation antibiotics to address current need for new antibiotics. Expert. Rev. Anti. Infect. Ther. 6, 593-600 (2008).
9. Brown, E. M. & Thomas, P. Fusidic acid resistance in Staphylococcus aureus isolates. Lancet359, 803 (2002).
10. Chang, S. C., Hsieh, S. M., Chen, M. L., Sheng, W. H. & Chen, Y. C. Oral fusidic acid failstoeradicate methicillin-resistant Staphylococcusaureuscolonization and results in emergence of fusidic acid-resistant strains. Diagn. Microbiol. Infect. Dis. 36, 131-136 (2000).
11. Ravenscroft, J. C., Layton, A. & Barnham, M. Observationson high levels offusidic acid resistant Staphylococcus aureus in Harrogate, North Yorkshire, UK. Clin. Exp. Dermatol. 25, 327-330 (2000).
12. Grundmann, H., Ires-de-Sousa, M. & Boyce, J. Emergence and resurgence of methi-cillin-resistant Staphylococcus aureus as a public-healththreat. Lancet368, 874-885 (2006).
13. Maviglia, R., Nestorini, R. & Pennisi, M. Role of old antibiotics in multidrug resistant bacterial infections. Curr. Drug. Targets 10, 895-905 (2009).
14. O'Brien, F. G., Botterill, C. I., Endersby, T. G., Lim, R. L. G., Grubb, W. B. & Gustafson, J. E. Heterogeneous expression of fusidic acid resistance in Staphylococcus aureus with plasmid or chromosomally encoded fusidic acid resistance genes. Pathology30, 299-303 (1998).
15. Forsgen, A. & Walder, M. Antimicrobial activity of fosfomycin in vitro. J. Antimicrob. Chemother. 11, 467-471 (1983).
16. Grif, K., Dierich, M. P., Pfaller, K., Miglioli, P. A. & Allerberger, F. In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J. Antimicrob. Chemother. 48, 209-217 (2001).
17. Morikawa, K., Oseko, F., Morikawa, S. & Sawada, M. Immunosuppressive activity of fosfomycin on human T-lymphocyte function in vitro. Antimicrob. Agents Chemother. 37, 2684-2687 (1993). (Pubitemid 23357868)
18. National Committeefor Clinical LaboratoryStandards (NCCLS). Performancestandards for antimicrobial susceptibilitytesting. InformationSupplementM100, S19 (2009).
19. Moody, J. Synergismtesting: broth microdilution checkerboard and broth macrodilution method. in Clinical Microbiology Procedures Handbook (ed. Isenberg, H. D.) 2nd edn, 1-28 (ASM Press: Washington, DC, 2004).
20. Carmona, P., Romá, E., Monte, E., García, J. & Gobernado, M. Papel de linezolid en terapéutica antimicrobiana. Enferm. Infecc. Microbiol. Clin. 21, 30-41 (2003).
21. Gobernado, M. Fosfomicina. Rev. Esp. Quimioterap. 16, 15-40 (2003).
22. Moreno, F., Crisp, C. & Jorgensen, J. H. Methicillin-resistant Staphylococcus aureusas a community organism. Clin. Infect. Dis. 21, 1308-1312 (1995).
23. Panlilio, A. L., Culver, D. H. &Gaynes, R. P. Methicillin-resistant Staphylococcus aureus in US hospitals, 1975-1991. Infect. Control Hosp. Epidemiol. 13, 582-586 (1992).
24. Robinson, D. A., Kearns, A. M. & Holmes, A. Re-emergence of early pandemic Staphylococcus aureus as a community-acquired methicillin-resistant clone. Lancet 365, 1256-1258 (2005).
25. Whitby, M. Fusidic acid in the treatment of methicillin-resistant Staphylococcus aureus. Int. J. Antimicrob. Agentsl2, S67-S71 (1999).
26. Grohs, P., Kitzis, M. D. & Gutmann, L. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus. Antimicrob. Agents Chemother. 47, 418-420 (2003).